Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04792489
Status:
RECRUITING
Last Update Posted:
2024-04-26
First Post:
2021-02-25
Brief Title:
DALY II USA MB-CART20191 for DLBCL
Sponsor:
Miltenyi Biomedicine GmbH
Organization:
Miltenyi Biomedicine GmbH
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Central Nervous System Lymphoma |
| Refractory Diffuse Large B Cell Lymphoma DLBCL |
| Relapsed Diffuse Large B Cell Lymphoma |
| High Grade B-cell Lymphoma HGBCL |
| Primary Mediastinal B-cell Lymphoma PMBCL |
| Transformed Lymphoma |
Keywords:
| Name | View |
|---|---|
| CD19CD20-directed CAR-T Cells | View |
| Zamtocabtagene autoleucel | View |
| B-Cell Non-Hodgkin Lymphoma | View |
| Primary Central Nervous System Lymphoma | View |
| Secondary Central Nervous System Lymphoma | View |
| NHL | View |
| PCNSL | View |
| SCNSL | View |
| Chimeric Antigen Receptor | View |
| CAR | View |
| CAR-T Cell | View |
| Autologous T Cell Therapy | View |
| Central Nervous System Neoplasms | View |
| Lymphoma | View |
| Lymphoma Non-Hodgkin | View |
| Lymphoma B-Cell | View |
| Lymphoma Large B-Cell Diffuse | View |